Table 1.
Characteristics of controls and children with early signs of NAFLD.
Fig 1.
(A) Endotoxin and (B) LBP plasma concentrations as well as (C) sCD14 serum concentrations and (D) D-lactate plasma levels in controls and children with early signs of NAFLD.
Data are shown as mean ± SEM, p < 0.05 is considered as significant compared to healthy control children. LBP: lipopolysaccharide-binding protein, sCD14: soluble CD14, NAFLD: non-alcoholic fatty liver disease.
Fig 2.
(A) PAI-1 plasma, (B) CRP serum and (C) IL-6 serum concentrations of controls and children with early signs of NAFLD.
Data are shown as mean ± SEM, p < 0.05 is considered to be significant compared to healthy control children. For the measurement of IL-6, n = 1 serum sample was insufficient. PAI-1: plasminogen activator inhibitor-1, CRP: c-reactive protein, IL-6: interleukin-6, NAFLD: non-alcoholic fatty liver disease.
Table 2.
Correlation analysis of markers of intestinal barrier function, inflammation and metabolic abnormalities.